Ignite Creation Date:
2024-05-06 @ 3:15 PM
Last Modification Date:
2024-10-26 @ 1:46 PM
Study NCT ID:
NCT04570332
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-01-29
First Post:
2020-09-22
Brief Title:
BO-112 With Pembrolizumab in Unresectable Malignant Melanoma
Sponsor:
Highlight Therapeutics
Organization:
Highlight Therapeutics